AstraZeneca Stays Hopeful About Ultomiris Despite Initial Conversion Difficulties

Sales of Soliris Successor Stumble

 
• By Ayisha Sharma

AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications. 

Finger pressing light switch button.
AstraZeneca Wants Patients To Switch From Soliris To Ultomiris • Source: Alamy

More from Business

More from Scrip